Hoilat Gilles Jadd, Suhail Fathima Keshia, Adhami Talal, John Savio
Department of Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, United States.
Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, OH 44195, United States.
World J Hepatol. 2022 Apr 27;14(4):670-681. doi: 10.4254/wjh.v14.i4.670.
Hepatic encephalopathy (HE) is a reversible syndrome of impaired brain function and represents one of the many complications of portal hypertension and decompensated liver disease. Although ammonia is clearly implicated in the pathogenesis of HE, the pathogenesis of HE is multifactorial with numerous mechanisms that results in functional impairment of neuronal cells. The initial management of HE focuses on supportive care and stabilization which includes providing appropriate nutritional support. Thereafter, focus should be on identifying and treating the precipitating factors. There are many therapeutic agents available for the management of HE, most of which are directed towards lowering the gut nitrogen load and thus the serum ammonia level. This review aims to provide an update on the conventional and emerging treatment options for HE.
肝性脑病(HE)是一种可逆的脑功能受损综合征,是门静脉高压和失代偿性肝病的众多并发症之一。尽管氨显然与HE的发病机制有关,但HE的发病机制是多因素的,有许多机制导致神经元细胞功能受损。HE的初始治疗重点是支持治疗和稳定病情,包括提供适当的营养支持。此后,应重点识别和治疗诱发因素。有许多治疗药物可用于治疗HE,其中大多数旨在降低肠道氮负荷,从而降低血清氨水平。本综述旨在提供关于HE传统和新兴治疗选择的最新信息。